Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Primary Diffuse Large B Cell Lymphoma of Bone: A Single-Center Experience.

Journal of blood medicine·2022

Same author

Inflammatory milieu in contrast-induced nephropathy: a prospective single-center study.

International journal of nephrology and renovascular disease·2018

Same author

The association of HLA-DQB10602 but not HLA-DRB115 with obstructive sleep apnea.

Clinical and investigative medicine. Medecine clinique et experimentale·2017

Same author

The association between metabolic syndrome and coronary artery disease in Jordan.

Chronic illness·2009

Search research articles

Related Experiment Video

Updated: May 8, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Evaluating single nucleotide polymorphisms in beta - 2 - microglobulin - a theoretical study.

Ammar K Daoud¹, Wafa' A Alqarqaz², Majduleen M Al Okor¹

¹Department of Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Frontiers in Immunology

|September 18, 2025

Summary

This summary is machine-generated.

Single Nucleotide Polymorphisms (SNPs) can alter Beta 2 Microglobulin (B2M) protein structure. Our analysis reveals that most SNPs cause significant amino acid substitutions, potentially impacting protein function and highlighting the need for improved computational tools.

Keywords:

amino acid substitutions beta 2 microglobulin genetics immunoglobulin domain superfamily single nucleotide polymorphism

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

Related Experiment Videos

Last Updated: May 8, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

Area of Science:

Immunology
Computational Biology
Genetics

Background:

Beta 2 Microglobulin (B2M) is a conserved single-domain protein within the Immunoglobulin Superfamily.
B2M exhibits a low rate of Single Nucleotide Polymorphisms (SNPs) across vertebrates.

Purpose of the Study:

To mathematically evaluate the impact of SNP-induced amino acid (AA) substitutions on the primary structure of B2M.
To assess the significance of these AA substitutions using established scoring systems.

Main Methods:

Developed a C++ program to analyze 360 B2M DNA sequences and predict corresponding 119 AA protein sequences.
Generated all possible 3 SNPs per nucleotide and assessed 9 modifications per triplet.
Utilized Sneath Score to evaluate the chemical resemblance of AA substitutions.

Main Results:

22.1% of SNPs resulted in no AA change; 25.4% caused minor changes within AA groups.
5.3% of SNPs generated stop codons, leading to premature transcription termination.
47.2% of SNPs resulted in significant AA substitutions across different chemical groups.

Conclusions:

SNPs in B2M are random events that can alter protein structure.
A significant proportion of SNPs lead to substantial AA changes, potentially affecting protein function.
There is a need for enhanced computational tools and scoring systems to accurately evaluate SNP effects on protein structure.